Search

Displaying results 931 - 940 of 5895 in total
  1. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.

  2. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder ...

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    OMS-103HP

    go.drugbank.com/drugs/DB05303
    Investigational

    OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.

  5. Drug

    Inosinic Acid

    go.drugbank.com/drugs/DB04566
    Investigational

    A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.

  6. Drug

    Succinylcholine

    go.drugbank.com/drugs/DB00202
    ApprovedInvestigational

    Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short

  7. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    [L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

  8. Drug

    Orphenadrine

    go.drugbank.com/drugs/DB01173
    ApprovedInvestigational

    A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

    Mixtures: MYOGESIC-OCategories: Ethers, Chemically Close to Antihistamines
  9. Drug

    Glipizide

    go.drugbank.com/drugs/DB01067
    ApprovedInvestigational

    Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. … According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin.

  10. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating … [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.